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SUMMARY
Introduction/Objective The pain that originates from musculoskeletal structures of the mastication 
system is one of the symptoms belonging to the category of temporomandibular disorders or temporo-
mandibular dysfunction (TMD). 
The objective of the research was to evaluate the effect of therapy with stabilizing occlusal splint in the 
control of painful symptoms of TMD in comparison with the effect of drug therapy.
Methods Using standard Research Diagnostic Criteria for Temporomandibular Disorders diagnostic 
protocol proposed by Dworkin and LeResche, a group of 44 patients with painful TMD was included. 
The patients were divided into three treatment groups by random selection. The first group was treated 
with stabilization occlusal splint for a period of one month. In the two control groups, therapy with 
non-steroidal anti-inflammatory drug ibuprofen (Brufen, Mylan, Canonsburg, PA, USA) or a combination 
therapy of ibuprofen and diazepam, a medication from the benzodiazepine family (Diazepam, Hemofarm, 
Vršac, Serbia) was carried out over a period of three weeks. In order to assess the effects of the therapy 
with stabilizing occlusal splint and the drug therapy, before and after the therapy, pain intensity measure-
ments were performed with visual analogue scale and digital pressure algometer.
Results A significant reduction in the intensity of painful symptoms was achieved in all three therapeutic 
groups. No significant differences in the effectiveness of pain reduction between the proposed thera-
peutic modalities were noted.
Conclusion The obtained results confirm that the therapy with stabilization occlusal splint is a valid 
procedure in the reduction of pain in patients with TMD.
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Pain in the orofacial region is a signal of tis-
sue damage and complicates most dental pro-
cedures. The presence of pain endangers the 
psycho-physical health and, indirectly, social 
and working abilities of patients. For the men-
tioned reasons, the first step in the treatment 
of various forms of temporomandibular dys-
function (TMD) is the reduction of the inten-
sity of pain and the relaxation of the mastica-
tion muscles [1, 2].
In the treatment of patients with signs and 
symptoms of painful TMD, different thera-
peutic modalities are used, which should not 
give negative side effects, nor cause irrevers-
ible structural changes in tissue [3]. The con-
cept of therapy with occlusal stabilization 
splint is based on several therapeutic mecha-
nisms, indirectly taking part in the control of 
painful symptoms and reducing the intensity 
of pain [4, 5].
The objective of the study was to examine 
in parallel the analgesic effect of the occlusal 
stabilization splint in relation to the effect 
of drug therapy in the reduction of painful 
symptoms in individuals with clinically con-
firmed signs of TMD.
METHODS
The research was conducted as a prospective 
study involving 44 subjects divided into three 
treatment groups heterogeneous by sex and 
age, who came to the Clinic for Prosthodontics, 
University of Belgrade, with TMD symptoms. 
A standardized protocol for TMD, proposed 
by Dworkin and LeResche [6], was used for 
diagnosing and numerically expressing pain 
intensity. Respondents were divided into three 
treatment groups formed by random selection 
based on the Research Diagnostic Criteria for 
Temporomandibular Disorders protocol. The 
first group consisted of 20 patients who re-
ceived therapy with a stabilization splint (Fig-
ures 1 and 2). The remaining 24 respondents 
were divided into two control groups that had 
therapy with non-steroidal anti-inflammatory 
drug ibuprofen (Brufen, Mylan, Canonsburg, 
PA, USA) or a combination therapy of ibupro-
fen and diazepam, a medicine from the ben-
zodiazepine family (Diazepam®, Hemofarm, 
Vršac, Serbia). All three groups were of equal 
age structure in the range of 25–45 years. The 
respondents were thoroughly informed about 
the protocol of the study and gave voluntary 
consent to participate in the study, which was 
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approved by the Ethics Commission of the Faculty of 
Dentistry, University of Belgrade. The chosen methodol-
ogy was applied to each patient individually.
Algometric measurement was performed in parallel 
with visual analogue scale (VAS) and digital algorithm. 
The pain threshold was measured by a digital algometer 
in the region of m. masseter and m. temporalis, on both 
sides. Measuring sites corresponded to palpable painful 
sites observed during the clinical examination. Painful 
places were previously marked with an ink pencil.
In order to measure the pressure threshold of the pain, 
the rubber tip of the algometer-probe was attached to the 
facial skin in the projection of the painful site, applied by 
a suitable procedure.
Measurement implied a gradual increase in mechani-
cal pressure to a painful place in the interval of 0.5 N/
sec. The respondent was instructed to verbally report the 
moment of pain. The measurement was repeated three 
times, with 5-minute pauses between the measurements. 
The measured force is displayed on the machine’s display 
in newtons (N). The pain threshold was defined as the 
moment in which the patient’s sense of pressure turned 
into a painful sensation. The pain threshold was calcu-
lated as the mean of the two last measurements, of three 
consecutive measurements.
The pressure measurement was performed at bilater-
ally symmetrical points. The respondent was informed 
that the same pressure force was applied on both sides. 
The intensity of the pain was measured in the same time 
and space conditions.
In order to minimize the error in algometer measur-
ing, the respondents were asked to avoid consuming alco-
hol, nicotine, and caffeine on the day of the measurement. 
The same procedure after the therapy had been admin-
istered was applied in all therapeutic groups. A digital 
algometer (FORSE ONETM FDIX, Wagner Instruments, 
Greenwich, CT, USA) was used in the research; it has a 
National Institute of Standards and Technology of the US 
Department of Commerce certificate, and is registered at 
the US Patent Office under the number 5,471,885.
Respondents in the control group were treated with 
combined therapy of ibuprofen (Brufen, Mylan, 400 mg, 
twice daily during a 12-hour period, after meals) and di-
azepam (Diazepam, Hemofarm, 5  mg, one hour before 
bedtime) over a period of three weeks, or with ibuprofen 
alone (400 mg, twice daily during a 12-hour period, after 
meals) during the same time frame. Since benzodiazepines 
are administered in smaller doses, the hypnotic effect of 
these drugs was avoided. Diazepam doses were gradually 
reduced before completion of therapy in order to avoid the 
recurrence of the disorder symptoms. Applied medicines 
have the ISO certificate and registration certificate at the 
Agency for Medicines and Medical Devices of Serbia.
PASW Statistics, Version 18.0 (SPSS Inc., Chicago, IL, 
USA) software was used for all statistical analysis. The 
level of statistical significance was set at p < 0.05.
RESULTS
The age of subjects with different orofacial pain treatment 
did not statistically significantly differ among subjects of 
different therapeutic groups. A statistically significant dif-
ference in the incidence of TMD was observed between 
different sexes. All subjects in the pharmaceutically treat-
ed group were female, while in the group treated with the 
stabilization splint there were 35% men and 65% women 
(Table 1).









respondents 8 20 16
Age (X ± SD) 44.63 ± 12.56 35.6 ± 10.7 38.5 ± 9.5 4 0.136a
Sex
n (%)
Male 0 (0%) 7 (35%) 0 (%)
0.007b,*
Female 8 (100%) 13 (65%) 16 (100%)
*Statistically significant difference; 
asingle-factor analysis of variance;  
bχ2 test
Between the analyzed groups treated with different 
therapeutic approaches, there was no statistically signifi-
cant difference in the cause of the existing pain. In the 
treatment group treated with analgesics and sedatives 
(62.5%), as well as in the group treated with the stabiliza-
tion splint (55%), the majority of subjects had musculo-
skeletal dysfunction, while in the group treated only with 
analgetics the frequency of subjects with joint and mus-
culoskeletal dysfunction was the same (37.5%) (Table 2).
Figure 2. Stabilization occlusal splint as a therapeutic option for pain 
reduction in patients with temporomandibular disorders
Figure 1. Stabilization splint made of thermoplastic poly-carbonate
Đorđević I. et al.
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Muscular 1 (12.5%) 2 (10%) 4 (25%)
0.657Articular 2 (25%) 7 (35%) 6 (37.5%)
Musculo-
skeletal 5 (62.5%) 11 (55%) 6 (37.5%)
Between the analyzed groups, treated with different 
therapeutic approaches, a statistically significant differ-
ence in the values of subjective intensity of pain (VAS) 
was not noticed before the therapy, nor after it. Between 
the analyzed therapeutic groups, there was no statistically 
significant difference in pain intensity with an objectively 
registered digital algometer (DA), before and after the 
performed therapy. A statistically significant difference in 
pain intensity was observed in all treatment groups be-
fore and after the therapy, regardless of the chosen treat-
ment method (Table 3).
Table 3. Subjective and objectively assessed intensity of pain before 









VAS’ 57.00 ± 21.29 59.05 ± 20.60 59.13 ± 15.61 0.962
VAS’’ 34.00 ± 18.99 28.55 ± 17.79 34.75 ± 17.73 0.553
VAS’ vs. VAS’’ p = 0.001* p = 0.000* p = 0.000*
DA’ 10.86 ± 1.81 11.27 ± 3.60 10.53 ± 2.25 0.751
DA’’ 15.42 ± 2.08 14.55 ± 3.76 15.14 ± 2.59 0.755
DA’ vs. DA’’ p = 0.001* p = 0.000* p = 0.000*
VAS’ – pain intensity assessed by visual analog scale before the therapy;  
VAS’’ – pain intensity assessed by visual analog scale after the therapy;  
DA’ – pain intensity assessed by digital algometer before the therapy;  
DA’’ – pain intensity assessed by digital algometer after the therapy; 
*statistically significant difference
A statistically significant correlation in the intensity of 
pain measured by the VAS scale and DA was observed. 
The correlation coefficient values obtained before and af-
ter therapy indicate the existence of a statistically signifi-
cant association, but the absolute values of the coefficients 
in both cases were less than 0.5, indicating the existence 
of significant deviations between the methods – that is, 
great subjective pain influence and evaluation on the VAS 
scale in respondents (Table 4).
Table 4. Correlation between different methods of measuring intensity 
of pain
Correlation VAS’ VAS’’ p
DA’ R = -0.473 0.001*
DA’’ R = -0.472 0.001*
DA’ – digital algometer before the therapy; DA’’ – digital algometer after the 
therapy; VAS’ – visual analogue scale before the therapy;  
VAS’’ – visual analogue scale after the therapy; 
*statistically significant correlation
By a correlation analysis of the current intensity value 
of the pain shown by the numerical scale and the score 
of pain in the VAS scale, a statistically significant correla-
tion was noted in the assessment of the pain measured 
by these instruments. Despite similar criteria of pain as-
sessment with these methods, the absolute value of the 
coefficient of correlation points to significant deviations 
in the assessment of the respondents for the same pain 
intensity experience (Table 5).
Table 5. Correlation of pain levels assessed in different ways




VAS’ – visual analogue scale before the therapy; DA’ – digital algometer before 
the therapy; NS – current pain; 
*statistically significant correlation
In order to evaluate the efficiency of different therapeu-
tic modalities for pain reduction, a multivariate regression 
model was used, where the severity of pain after treatment 
was assessed by the VAS and DA methods. In this regres-
sion model, the effect of all observed risk factors, pretreat-
ment factors, applied therapies, and other outcomes (de-
pression, psychosocial status) were evaluated, on the evalu-
ation of pain by the VAS and DA methods after therapy.





#B (95%CI) p B (95%CI) p
Sex 6.529  (-8.326–21.384) 0.380 / /
Age 0.179  (-0.327–0.686) 0.479 / /
VAS’ 0.608  (0.378–0.838) 0.000*
0.426  
(0.115–0.737) 0.009*
DA’ -2.658  (-4.418–-0.899) 0.004*
-0.931  
(-2.655–0.794) 0.281
Therapy 1.315  (-6.336–8.965) 0.731 / /




























Depression 9.082  (1.696–16.467) 0.017*
1.164  
(-6.141–8.468) 0.748
VAS’’ – visual analogue scale after the therapy; VAS’ – visual analogue scale 
before the therapy; DA’ – digital algometer before the therapy; 
*statistically significant; 
#non-standardized coefficient B
In the measurement of VAS pain by scaling, a univari-
ate regression analysis found that pain after the applied 
therapy was associated with the pain described before the 
start of treatment, the assessment of working ability, social 
life, everyday activities, chronic pain, reduction of orofa-
cial functions, and depression (Table 6). The intensity of 
pain measured prior to the therapy by the VAS and the as-
sessment of social life were singled out, as the predictors 
Occlusal appliances – an alternative in pain treatment of temporomandibular disorders 
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of post-therapeutic intensity of pain. Respondents who 
complained of severe pain before initiating therapy had 
a higher intensity of pain after the applied treatment. In 
all subjects with pain in the orofacial region, regardless of 
pain reduction after therapy, one can always expect the 
influence of pain on their social life, which is more dis-
turbed as the pain is stronger.
When assessing post-treatment pain measured with 
the DA, the univariate regression analysis as statistically 
significant included sex, strength of the pain measured 
by the DA before treatment, and the pain level after treat-
ment measured on the VAS scale. Multivariant regression 
analysis, the severity of pain measured by the DA before 
therapy and the measurement of VAS after therapy, have 
been singled out as factors with an independent impact 
on the severity of pain, measured by the same method 
after therapy (Table 7).





#B (95%CI) p B (95% CI) p
Sex -2.868  (-5.294–-0.442) 0.022*
-0.690  
(-2.638–1.258) 0.478
Age -0.024  (-0.112–0.063) 0.577 / /
VAS’ -0.040  (-0.090–0.010) 0.115 / /
DA’ 0.766  (0.530–1.001) 0.000*
0.634  
(0.358–0.911) 0.000*
Therapy -0.022  (-1.343–1.299) 0.973 / /
VAS’’ -0.081  (-0.129–0.034) 0.001*
-0.036  
(-0.129–0.034) 0.005*




(-0.424–0.470) 0.919 / /












(-1.158–0.313) 0.253 / /
Depression -0.323  (-1.683–1.036) 0.634 / /
DA’ – digital algometer before the therapy; DA’’ – digital algometer after the 
therapy; VAS’ – visual analogue scale before the therapy; VAS’’ – visual ana-




Pain is not only a signal of tissue damage, but also a dif-
ficulty in most dental procedures, delaying the rehabilita-
tion of functions and reducing the chances of a patient 
returning. Pain control is often inadequate, either due 
to insufficient analgesia or due to unacceptable side ef-
fects of drug therapy. In addition, inadequate analgesia 
can contribute to the onset of hyperalgesia during the 
recovery period. The aforementioned facts indicate that 
it is imperative to have effective analgesia with minimal 
side effects. Pain, as a symptom of TMDs and associated 
dysfunction of the mastication muscles and TM joints, 
is a significant entity of TMD. A simple and reliable de-
termination of the origin of pain is detrimental for the 
choice of therapeutic modality. Multifactorial etiology 
and overlapping of symptoms and signs of various TMDs 
complicate this requirement [7]. An additional problem 
in the choice of therapeutic approach lies in the fact that 
pain, as the most prominent symptom, can occur second-
ary, as a result of disorders of adjacent structures. Since 
the causes of TMD and the interaction between different 
entities of TMD are very complex, initial therapy should 
be non-invasive and reversible. In this respect, occlusal 
splint represents the therapy of choice, since it temporar-
ily improves the functional relationship of the structures 
of the orofacial (OF) system. The occlusal splint, acting 
on the cause of the disorder, influences symptoms, and 
also plays a role as a diagnostic agent. This fact is par-
ticularly important in cases when there is a suspicion of 
the dominant influence of occlusal factors in the develop-
ment of TMD. Detailed mechanisms by which occlusal 
splints achieve these results are still the subject of discus-
sion [8]. Stabilization splint is sometimes referred to as 
the relaxation splint due to its primary application in the 
reduction of muscle pain [9].
The results of this study indicate a positive effect of the 
stabilization splint in the reduction of painful symptoms 
regardless of the TMD, as there is a statistically significant 
difference in the measured intensity of pain in all treatment 
groups before and after the applied therapy (p ≤ 0.05). All 
subjects of the clinical population who were male (15.9%) 
were treated physically with an occlusal stabilization 
splint exclusively. In the therapeutic group treated with a 
stabilization splint (55%), the majority of subjects had a 
diagnosed musculoskeletal dysfunction. The majority of 
respondents with moderate depression were in the treat-
ment group treated with occlusal splint (45%), as well as 
subjects without defined depression (45%). Positive effects 
of stabilization pain therapy in pain reduction were ob-
served in many studies [10–14]. Stabilization splints, as 
splints of flat surfaces, are conventionally made of solid 
material. Such splints are resistant to the long-lasting ef-
fect of occlusal forces of varying intensity and satisfies the 
requirements of physiologically optimal and stable occlu-
sion [15]. Solid-type splints reduce the electromyographic 
activity of the masseter and temporal muscles [16].
Lazić et al. [17] carried out a comparative analysis 
of the mechanical and chemical properties, structure, 
surface of PMMA breaks, and thermoplastic polymers. 
The results of the tests indicate that thermoplastic poly-
carbonate (TPK) materials are more suitable for making 
occlusal splints, since the beginning of the deformation 
is elastic, and they also have a potency of flow and charac-
teristics of viscoelastic polymers. Mechanical properties 
and appearance of faulty surfaces imposes the use of TPK 
materials for making occlusal splints [17].
DOI: https://doi.org/10.2298/SARH190118064D
Đorđević I. et al.
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The choice of splint as a therapeutic agent in the treat-
ment of painful TMDs requires caution and a properly 
diagnosed dysfunction. Also, limited therapeutic capac-
ity should be taken into account as well as possible com-
plications during the wearing of such compensation (car-
ies of the tooth below the splint, gingivitis due to poor 
oral hygiene, difficult speech and breathing functions, 
and eventual psychosomatic reactions to foreign bodies). 
These facts imply the obligation to conduct regular and 
frequent check-ups after giving splint to the patient.
Given that the studied population consisted of patients 
who sought help regarding treatment of TMD, we can say 
that respondents belong to the clinical population. Of the 
44 patients in the clinical population who exposed the 
signs and symptoms of TMD, 22 subjects (50%) had a 
combined musculoskeletal dysfunction. Fifteen respon-
dents (34.1%) showed symptoms of articular dysfunction 
regardless of the possibility of condyle reduction or of the 
degree of mouth opening, and seven respondents (15.1%) 
showed symptoms and signs of muscular dysfunction re-
gardless of the degree of mouth opening. In this regard, 
the results of the study on the distribution of various sub-
groups of TMD are similar to the results of many studies 
[18, 19, 20].
Differences in the frequency and distribution of TMD 
subgroups are due to different criteria of homogeniza-
tion of the examined population and various diagnostic 
methods. In addition, there is a difference in the type of 
population surveyed (clinical or general), as well as in the 
age of the population group.
By analyzing the distribution of TMD among the sexes 
in the clinical population, the results show that the inci-
dence of symptoms and signs of TMD is six times higher in 
females than in males. Of the 44 subjects who were includ-
ed in the study, 15.9% of the respondents were male. The 
high incidence of TMD in women is considered to be the 
consequence of greater responsibility of women towards 
their own health and more frequent visits to the doctor, 
and that women are more affected by stress [20, 21].
The available methods vary significantly among re-
searchers, which does not allow for a comparison of dif-
ferent studies. The most common problems in compar-
ing the results of other studies lie in different time frames 
given to respondents to evaluate the pain. While some re-
searchers require information on the current intensity of 
pain, others require that respondents rank the pain level 
over the previous 24 hours. This is one of the reasons for 
the existence of variability of the results [22, 23].
A statistically significant correlation was observed in 
the measured intensity of pain with the VAS scale and the 
DA method, which also indicates the existence of signifi-
cant discrepancies between the measurement methods, 
i.e. the great influence of subjective pain experience and 
the assessment on the VAS scale. In addition, some studies 
point to the unreliability of the digital algorithm method 
by pressing force in successive measurements [24].
The inconsistency of the results of the multivariate re-
gression analysis for pain measured by the VAS scale and 
the algometric method after the applied treatment is an-
other confirmation of the quality of VAS as an instrument 
for subjective assessment of the pain experience. Given that 
the experience of pain is an individual category involved in 
the psychosocial life of an individual, despite the bias that 
the VAS scale implies in the assessment of pain, a compara-
tive application of the VAS scale with other instruments for 
measuring the intensity of pain is necessary.
In any case, one should be cautious in interpreting the 
results for at least three reasons. The first one is that pa-
tients with chronic pain have normal adjustment to the 
existing conditions, whether or not therapy is performed, 
and symptom regression occurs. Another reason for 
symptom regression is the consequence of the doctor–pa-
tient interaction. Patient encouragement and information 
on the causative agent and benign character of the disease 
leave a positive effect on the patient and his presentation 
of the symptoms of pain [25].
The third reason lies in the fact that the pain regres-
sion is also influenced by psychosocial factors, primarily 
the quality of life, social and cultural status, and previous 
painful experiences [26].
CONCLUISION
The study found that the intensity of the pain is not a 
predictor of the dysfunction of the orofacial system. 
Considering the objectives of the study, the analysis of 
the obtained results suggests that therapy with an occlu-
sal stabilization splint can significantly reduce the pain 
intensity and confirmes the positive analgesic effect of 
occlusal stabilization splint in TMD patients. All thera-
peutic modalities applied in this study have proved to be 
equally effective in reducing painful symptoms so that the 
prognostic significance of the intensity of pain measured 
before treatment is irrelevant. Significant deviation in 
respondents’ assessments of the same pain intensity ex-
perience, depending on the type of the measuring instru-
ment, was also found.
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САЖЕТАК
Увод/Циљ Бол порекла мишићно-скелетних структура 
мастикаторног система представља један од симптома који 
припадају категорији темпоромандибуларних поремећаја 
или темпоромандибуларних дисфункција (ТМД). 
Циљ истраживања је био да се процени ефекат терапије 
стабилизационим оклузалним сплинтом у контроли болних 
симптома ТМД у поређењу са ефектом терапије лековима.
Методе Коришћењем стандардног дијагностичког протоко-
ла (RDC/ТМД) предложеног од стране Дворкина и Лерешеа, 
издвојена је група од 44 болесника са болним темпороман-
дибуларним дисфункцијама. Болесници су подељени у три 
терапијске групе случајним избором. Прва група је подвр-
гнута терапији стабилизационим оклузалним сплинтом у 
периоду од месец дана. У две контролне групе је спроведена 
терапија нестероидним антиинфламаторним леком ибуп-
рофеном (бруфен, Mylan) или комбинацијом ибупрофена и 
лека из групе бензодиазепина – диазепамa (диазепам, Хе-
мофарм) у периоду од три недеље. У циљу процене ефеката 
терапије стабилизационим оклузалним сплинтом и терапије 
лековима, пре и после спроведене терапије изведена су 
мерења интензитета бола визуелном аналогном скалом и 
дигиталним притисним алгометром. 
Резултати У све три терапијске групе постигнуто је значајно 
смањење интензитета болних симптома. Нису забележене 
значајне разлике у успешности смањења бола између пред-
ложених терапијских модалитета. 
Закључак Добијени резултати потврђују да је терапија ста-
билизационим оклузалним сплинтом валидна процедура у 
смањењу бола код болесника са ТМД. 
Кључне речи: темпоромандибуларне дисфункције; оклуза-
лни сплинт; фармакотерапија
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